Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high ...

I am reversing my rating on Akero Therapeutics stock from Buy to Sell due to valuation concerns and a long-ish wait for ...

Here is how Akero Therapeutics, Inc. (AKRO) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

Detailed price information for Apellis Pharmaceuticals Inc (APLS-Q) from The Globe and Mail including charting and trades.

Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the ...

Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the EASL Congress 2025 highlighted data demonstrating statistically significant ...

Akero Therapeutics Inc. research and ratings by Barron's. View 1AKRO revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

Fintel reports that on August 4, 2025, TD Cowen initiated coverage of Akero Therapeutics (NasdaqGS:AKRO) with a Buy ...

Andrew Cheng, President and CEO of Akero Therapeutics, Inc. (NASDAQ: AKRO), sold 6,620 shares of common stock on June 18, 2025, according to a Form 4 filing with the Securities and Exchange Commission ...

Akero Therapeutics (NASDAQ: AKRO) Chief Technology Officer Scott A. Gangloff sold 848 shares of common stock on June 18, 2025, at prices ranging from $54.73 to $54.84, for a total value of $46,504.

Akero Therapeutics, Inc. (NASDAQ: AKRO) Senior Vice President, Commercial Strategy, Patrick Lamy, sold 2,000 shares of common stock on June 16, 2025, for a total of $108,271. The sales were executed ...